AZD-5423 is a nonsteroidal glucocorticoid and Phases of clinical research, phase II experimental drug being developed by AstraZeneca
and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease.
It has completed a phase II clinical trial.
See also
* Dagrocorat
* Fosdagrocorat
* Mapracorat
References
External links
AZD-5423 - AdisInsight
Phenylethanolamine ethers
Glucocorticoids
Indazoles
Trifluoromethyl compounds
Respiratory agents
Acetamides
Fluoroarenes
{{respiratory-system-drug-stub